BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,050.65
- Market cap
- ₹20,652 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.5×Sector 48.6×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.2 Cr · +81.5% YoY
Other regulatory approval announcements
All →Senores Pharmaceuticals Regulatory Approval
Senores Pharmaceuticals disclosed that its subsidiary Ratnatris Pharmaceuticals' Mehsana facility received PIC/S GMP certification from Ukraine's SMDC. The certificate, issued 16 November 2026, opens a wider pathway to regulatory approvals.
Xtglobal Infotech Regulatory Approval
XTGlobal received RBI approval for a ₹0.10 Crore (EUR 10,000) equity investment in its Irish subsidiary. The initial capital supports its European expansion plans.
- Value
- ₹0.10 Cr
Regal Entertainment & Consultants Regulatory Approval
Regal Entertainment received RBI approval for Satbir Singh's appointment as Executive Director. Shareholder approval is still pending, with the term running to April 4, 2028.
Biocon Regulatory Approval
Biocon received U.S. FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, its fifth oncology biosimilar approved in the US. A global settlement with Genentech sets the earliest US launch in Q3 2028.
United Breweries Regulatory Approval
United Breweries received BIADA's final order restoring its 42-acre Patna land allotment under the Amnesty Policy 2025, subject to conditions. Commercial production milestones must be met within 24 months.
Bhageria Industries Regulatory Approval
Bhageria Industries received EDQM attestation of GMP inspection for its Vapi facility, confirming EU GMP compliance for Dexamethasone under CEP No. 2024-138. No monetary value is disclosed.